Lenalidomide Thorton & Ross Ltd. (Lenalidomide)

Lenalidomide binds to the cereblon protein within the CRL4‑E3 ubiquitin ligase complex, altering the degradation of specific transcription factors. This action suppresses tumor cell growth, inhibits new blood‑vessel formation, and enhances immune‑mediated killing of malignant cells, providing antineoplastic effects.

The prescribed dose of lenalidomide is individualized by the treating physician based on the specific indication, patient characteristics, renal function, and concomitant therapies. Only a qualified healthcare provider can determine the appropriate regimen for each patient.

Lenalidomide is classified as having an unknown pregnancy category and is considered teratogenic. It should not be used by pregnant women, and effective contraception is required for both male and female patients of reproductive potential. Breastfeeding is not recommended while on therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both lenalidomide and thalidomide belong to the immunomodulatory drug class, but lenalidomide has a more favorable safety profile, stronger anti‑angiogenic activity, and greater potency in certain hematologic cancers. Clinical choice depends on the specific disease, prior therapies, and individual patient tolerance.

Lenalidomide tablets should be stored at temperatures below 25 °C, in their original packaging, and protected from moisture and direct sunlight. Keeping the product in a dry, controlled environment helps maintain its stability and potency throughout its shelf life.

Lenalidomide is taken orally, usually with or without food, as directed by the prescribing clinician. The tablets should be swallowed whole with water and not crushed or chewed unless specifically instructed by a healthcare professional.

The most serious risks include venous thromboembolism, severe cutaneous reactions such as Stevens‑Johnson syndrome, and the potential development of secondary primary malignancies. Patients should be monitored closely for signs of these events and report any concerning symptoms promptly.

Lenalidomide is contraindicated in patients who are pregnant, those who cannot use effective contraception, and individuals with known hypersensitivity to the drug or its excipients. It should also be used with caution in patients with severe renal impairment or a history of thromboembolic events.